Press Releases

12.15.2023

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer

12.14.2023

Pfizer Declares First-Quarter 2024 Dividend

12.14.2023

Pfizer Completes Acquisition of Seagen

12.13.2023

Pfizer Provides Full-Year 2024 Guidance

12.12.2023

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

12.11.2023

FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B

12.09.2023

Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B

12.08.2023

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma

12.01.2023

Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity

11.21.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

11.02.2023

Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting

11.02.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference